{"id":"long-term-androgen-deprivation","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"70-90","effect":"Erectile dysfunction"},{"rate":"60-80","effect":"Decreased libido"},{"rate":"10-30","effect":"Gynecomastia"},{"rate":"20-50","effect":"Bone loss/osteoporosis"},{"rate":"30-50","effect":"Fatigue"},{"rate":"20-40","effect":"Weight gain"},{"rate":"15-30","effect":"Metabolic syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic approach reduces circulating androgens through chemical or surgical castration, depriving prostate cancer cells of the hormonal signals required for proliferation. By maintaining sustained low testosterone levels over extended periods, the treatment aims to control disease progression in hormone-sensitive prostate cancer. This is a standard endocrine therapy approach for advanced prostate cancer management.","oneSentence":"Long-term androgen deprivation therapy suppresses testosterone production to inhibit the growth of androgen-dependent prostate cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:23.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic hormone-sensitive prostate cancer"},{"name":"Locally advanced prostate cancer (in combination with radiation therapy)"}]},"trialDetails":[{"nctId":"NCT07426094","phase":"PHASE2, PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1600},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07364071","phase":"PHASE2","title":"Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":"Prostate Adenocarcinoma","enrollment":150},{"nctId":"NCT00579072","phase":"","title":"The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-08","conditions":"Prostate Cancer","enrollment":230},{"nctId":"NCT00117286","phase":"PHASE2, PHASE3","title":"Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-03","conditions":"Prostate Cancer","enrollment":57},{"nctId":"NCT06150417","phase":"PHASE2","title":"MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-07-01","conditions":"Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate","enrollment":200},{"nctId":"NCT06824818","phase":"NA","title":"Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-06","conditions":"Elderly, Prostate Cancer","enrollment":155},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT01488968","phase":"NA","title":"Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2012-03","conditions":"High-risk Prostate Cancer","enrollment":111},{"nctId":"NCT04067713","phase":"","title":"Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-09-20","conditions":"Metastatic Prostate Cancer","enrollment":192},{"nctId":"NCT02799706","phase":"PHASE3","title":"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-09-25","conditions":"Prostate Cancer","enrollment":885},{"nctId":"NCT01985828","phase":"NA","title":"CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-11-19","conditions":"Prostate Adenocarcinoma","enrollment":83},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT01555632","phase":"NA","title":"Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2012-03","conditions":"Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":""},{"nctId":"NCT02015871","phase":"PHASE3","title":"An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2014-01","conditions":"Prostate Cancer","enrollment":206},{"nctId":"NCT02064036","phase":"PHASE1","title":"Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06-06","conditions":"Adenocarcinoma of the Prostate","enrollment":17},{"nctId":"NCT05212857","phase":"PHASE2","title":"Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-04","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00058188","phase":"PHASE3","title":"Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-03","conditions":"Osteoporosis, Prostate Cancer","enrollment":53},{"nctId":"NCT02175212","phase":"PHASE3","title":"Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2005-11","conditions":"Prostate Adenocarcinoma","enrollment":362},{"nctId":"NCT01117935","phase":"NA","title":"Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2010-05-30","conditions":"Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer","enrollment":55},{"nctId":"NCT01811810","phase":"NA","title":"Proton Therapy for High Risk Prostate Cancer","status":"WITHDRAWN","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-03","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01383863","phase":"","title":"A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Advanced Prostate Cancer","enrollment":180},{"nctId":"NCT00838201","phase":"PHASE3","title":"Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02-01","conditions":"Cancer, Carcinoma, Castrate-Resistant Prostate Cancer","enrollment":384},{"nctId":"NCT01242748","phase":"PHASE3","title":"A Degarelix Trial in Patients With Prostate Cancer","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-10","conditions":"Prostate Cancer","enrollment":288},{"nctId":"NCT00215683","phase":"PHASE2, PHASE3","title":"An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-02","conditions":"Prostate Cancer","enrollment":137},{"nctId":"NCT01704027","phase":"PHASE2","title":"Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"Centre Georges Francois Leclerc","startDate":"2012-10","conditions":"Prostate Cancer","enrollment":28},{"nctId":"NCT01981668","phase":"PHASE1","title":"The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation","status":"WITHDRAWN","sponsor":"Nova Scotia Cancer Centre","startDate":"","conditions":"Prostatic Neoplasms","enrollment":""},{"nctId":"NCT00767286","phase":"PHASE3","title":"Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01215513","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-09","conditions":"Prostate Cancer","enrollment":127},{"nctId":"NCT01839994","phase":"PHASE3","title":"Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2013-06","conditions":"Prostate Cancer","enrollment":350},{"nctId":"NCT00451958","phase":"PHASE3","title":"A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":386},{"nctId":"NCT00743327","phase":"","title":"Androgen Deprivation Therapy Study","status":"TERMINATED","sponsor":"National Institute on Aging (NIA)","startDate":"2008-10","conditions":"Hypogonadism, Metabolic Syndrome, Diabetes","enrollment":1},{"nctId":"NCT00117312","phase":"PHASE2","title":"Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2002-10","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT00245466","phase":"PHASE2","title":"Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2001-10","conditions":"Prostate Cancer","enrollment":88},{"nctId":"NCT00268892","phase":"PHASE2, PHASE3","title":"Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2006-01","conditions":"Prostate Cancer","enrollment":278},{"nctId":"NCT00536653","phase":"NA","title":"Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Wirral University Teaching Hospital NHS Trust","startDate":"1999-10","conditions":"Osteoporosis","enrollment":618}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":237,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neoadjuvant, concomitant and adjuvant"],"phase":"phase_3","status":"active","brandName":"Long term androgen deprivation","genericName":"Long term androgen deprivation","companyName":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","companyId":"fundaci-n-de-investigaci-n-biom-dica-hospital-universitario-de-la-princesa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-term androgen deprivation therapy suppresses testosterone production to inhibit the growth of androgen-dependent prostate cancer cells. Used for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}